Key result
High critical care therapy utilization shows no adjusted mortality benefit despite higher unadjusted mortality.
Why the study?
Wide interhospital variations exist in CICU admission practices and use of critical care restricted therapies, but differences in patient acuity, CCRx utilization, and outcomes within tertiary centers are not well understood.
Does hospital-level utilization of critical care restricted therapies impact adjusted in-hospital mortality for intensive care admissions?
Observational (n=17,843)
Yes
Does hospital-level utilization of critical care restricted therapies impact adjusted in-hospital mortality for intensive care admissions?
Answers are grounded in this paper and cite their sources.
While unadjusted mortality varies with the intensity of critical care therapy utilization, there is no significant difference in adjusted mortality, suggesting variations are driven primarily by patient acuity.
BACKGROUND: Wide interhospital variations exist in cardiovascular intensive care unit (CICU) admission practices and the use of critical care restricted therapies (CCRx), but little is known about the differences in patient acuity, CCRx utilization, and the associated outcomes within tertiary centers. METHODS: The Critical Care Cardiology Trials Network is a multicenter registry of tertiary and academic CICUs in the United States and Canada that captured consecutive admissions in 2-month periods between 2017 and 2022. This analysis included 17 843 admissions across 34 sites and compared interhospital tertiles of CCRx (eg, mechanical ventilation, mechanical circulatory support, continuous renal replacement therapy) utilization and its adjusted association with in-hospital survival using logistic regression. The Pratt index was used to quantify patient-related and institutional factors associated with CCRx variability. RESULTS: The median age of the study population was 66 (56-77) years and 37% were female. CCRx was provided to 62.2% (interhospital range of 21.3%-87.1%) of CICU patients. Admissions to CICUs with the highest tertile of CCRx utilization had a greater burden of comorbidities, had more diagnoses of ST-elevation myocardial infarction, cardiac arrest, or cardiogenic shock, and had higher Sequential Organ Failure Assessment scores. The unadjusted in-hospital mortality (median, 12.7%) was 9.6%, 11.1%, and 18.7% in low, intermediate, and high CCRx tertiles, respectively. No clinically meaningful differences in adjusted mortality were observed across tertiles when admissions were stratified by the provision of CCRx. Baseline patient-level variables and institutional differences accounted for 80% and 5.3% of the observed CCRx variability, respectively. CONCLUSIONS: In a large registry of tertiary and academic CICUs, there was a >4-fold interhospital variation in the provision of CCRx that was primarily driven by differences in patient acuity compared with institutional differences. No differences were observed in adjusted mortality between low, intermediate, and high CCRx utilization sites.
No takes yet. Share an insight, caveat, or question.
Donnelly et al. (2024) conducted an observational in Cardiovascular intensive care unit (CICU) admissions (n=17,843). High critical care restricted therapies (CCRx) utilization vs. Low and intermediate CCRx utilization was evaluated on In-hospital mortality (adjusted association) (No clinically meaningful differences in adjusted mortality). High utilization of critical care restricted therapies was associated with higher unadjusted mortality, but no clinically meaningful differences were observed in adjusted mortality.
Synapse has enriched 10 related papers. Consider them for comparative context: